Nicotine modulation of fear memories and anxiety: Implications for learning and anxiety disorders

Munir Gunes Kutlu, Thomas J. Gould

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Anxiety disorders are a group of crippling mental diseases affecting millions of Americans with a 30% lifetime prevalence and costs associated with healthcare of $42.3 billion. While anxiety disorders show high levels of co-morbidity with smoking (45.3% vs. 22.5% in healthy individuals), they are also more common among the smoking population (22% vs. 11.1% in the non-smoking population). Moreover, there is clear evidence that smoking modulates symptom severity in patients with anxiety disorders. In order to better understand this relationship, several animal paradigms are used to model several key symptoms of anxiety disorders; these include fear conditioning and measures of anxiety. Studies clearly demonstrate that nicotine mediates acquisition and extinction of fear as well as anxiety through the modulation of specific subtypes of nicotinic acetylcholine receptors (nAChRs) in brain regions involved in emotion processing such as the hippocampus. However, the direction of nicotine's effects on these behaviors is determined by several factors that include the length of administration, hippocampus-dependency of the fear learning task, and source of anxiety (novelty-driven vs. social anxiety). Overall, the studies reviewed here suggest that nicotine alters behaviors related to fear and anxiety and that nicotine contributes to the development, maintenance, and reoccurrence of anxiety disorders.

Original languageEnglish (US)
Pages (from-to)498-511
Number of pages14
JournalBiochemical Pharmacology
Volume97
Issue number4
DOIs
StatePublished - Oct 15 2015

Fingerprint

Learning Disorders
Anxiety Disorders
Nicotine
Fear
Anxiety
Modulation
Data storage equipment
Smoking
Hippocampus
Nicotinic Receptors
Brain
Animals
Population
Emotions
Maintenance
Learning
Morbidity
Delivery of Health Care
Costs and Cost Analysis
Processing

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

@article{5f1eb013b4e8404f8f40660600ce645d,
title = "Nicotine modulation of fear memories and anxiety: Implications for learning and anxiety disorders",
abstract = "Anxiety disorders are a group of crippling mental diseases affecting millions of Americans with a 30{\%} lifetime prevalence and costs associated with healthcare of $42.3 billion. While anxiety disorders show high levels of co-morbidity with smoking (45.3{\%} vs. 22.5{\%} in healthy individuals), they are also more common among the smoking population (22{\%} vs. 11.1{\%} in the non-smoking population). Moreover, there is clear evidence that smoking modulates symptom severity in patients with anxiety disorders. In order to better understand this relationship, several animal paradigms are used to model several key symptoms of anxiety disorders; these include fear conditioning and measures of anxiety. Studies clearly demonstrate that nicotine mediates acquisition and extinction of fear as well as anxiety through the modulation of specific subtypes of nicotinic acetylcholine receptors (nAChRs) in brain regions involved in emotion processing such as the hippocampus. However, the direction of nicotine's effects on these behaviors is determined by several factors that include the length of administration, hippocampus-dependency of the fear learning task, and source of anxiety (novelty-driven vs. social anxiety). Overall, the studies reviewed here suggest that nicotine alters behaviors related to fear and anxiety and that nicotine contributes to the development, maintenance, and reoccurrence of anxiety disorders.",
author = "Kutlu, {Munir Gunes} and Gould, {Thomas J.}",
year = "2015",
month = "10",
day = "15",
doi = "10.1016/j.bcp.2015.07.029",
language = "English (US)",
volume = "97",
pages = "498--511",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

Nicotine modulation of fear memories and anxiety : Implications for learning and anxiety disorders. / Kutlu, Munir Gunes; Gould, Thomas J.

In: Biochemical Pharmacology, Vol. 97, No. 4, 15.10.2015, p. 498-511.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Nicotine modulation of fear memories and anxiety

T2 - Implications for learning and anxiety disorders

AU - Kutlu, Munir Gunes

AU - Gould, Thomas J.

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Anxiety disorders are a group of crippling mental diseases affecting millions of Americans with a 30% lifetime prevalence and costs associated with healthcare of $42.3 billion. While anxiety disorders show high levels of co-morbidity with smoking (45.3% vs. 22.5% in healthy individuals), they are also more common among the smoking population (22% vs. 11.1% in the non-smoking population). Moreover, there is clear evidence that smoking modulates symptom severity in patients with anxiety disorders. In order to better understand this relationship, several animal paradigms are used to model several key symptoms of anxiety disorders; these include fear conditioning and measures of anxiety. Studies clearly demonstrate that nicotine mediates acquisition and extinction of fear as well as anxiety through the modulation of specific subtypes of nicotinic acetylcholine receptors (nAChRs) in brain regions involved in emotion processing such as the hippocampus. However, the direction of nicotine's effects on these behaviors is determined by several factors that include the length of administration, hippocampus-dependency of the fear learning task, and source of anxiety (novelty-driven vs. social anxiety). Overall, the studies reviewed here suggest that nicotine alters behaviors related to fear and anxiety and that nicotine contributes to the development, maintenance, and reoccurrence of anxiety disorders.

AB - Anxiety disorders are a group of crippling mental diseases affecting millions of Americans with a 30% lifetime prevalence and costs associated with healthcare of $42.3 billion. While anxiety disorders show high levels of co-morbidity with smoking (45.3% vs. 22.5% in healthy individuals), they are also more common among the smoking population (22% vs. 11.1% in the non-smoking population). Moreover, there is clear evidence that smoking modulates symptom severity in patients with anxiety disorders. In order to better understand this relationship, several animal paradigms are used to model several key symptoms of anxiety disorders; these include fear conditioning and measures of anxiety. Studies clearly demonstrate that nicotine mediates acquisition and extinction of fear as well as anxiety through the modulation of specific subtypes of nicotinic acetylcholine receptors (nAChRs) in brain regions involved in emotion processing such as the hippocampus. However, the direction of nicotine's effects on these behaviors is determined by several factors that include the length of administration, hippocampus-dependency of the fear learning task, and source of anxiety (novelty-driven vs. social anxiety). Overall, the studies reviewed here suggest that nicotine alters behaviors related to fear and anxiety and that nicotine contributes to the development, maintenance, and reoccurrence of anxiety disorders.

UR - http://www.scopus.com/inward/record.url?scp=84943351579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943351579&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2015.07.029

DO - 10.1016/j.bcp.2015.07.029

M3 - Review article

C2 - 26231942

AN - SCOPUS:84943351579

VL - 97

SP - 498

EP - 511

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -